查看购物车
  • Traditional Chinese
  • English
  • Japanese
庞贝氏症治疗市场规模、份额、成长分析（按类型、诊断、疾病类型、治疗方法、给药途径、分销管道、最终用户、地区划分）－2025-2032年产业预测
市场调查报告书
商品编码
1854252

庞贝氏症治疗市场规模、份额、成长分析（按类型、诊断、疾病类型、治疗方法、给药途径、分销管道、最终用户、地区划分）－2025-2032年产业预测

Pompe Disease Treatment Market Size, Share, and Growth Analysis, By Type, By Diagnosis, By Disease Type, By Treatment, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2025-2032
出版日期: | 出版商: SkyQuest | 英文 191 Pages | 商品交期: 3-5个工作天内

价格
简介目录

全球庞贝氏症治疗市场预计在 2023 年达到 21 亿美元，从 2024 年的 22.4 亿美元成长到 2032 年的 38.3 亿美元，在预测期（2025-2032 年）内复合年增长率为 6.9%。

受发病率上升和对有效治疗方法需求增加的推动，全球庞贝氏症治疗市场正经历强劲增长。诊断能力的提升以及医护人员和患者对此疾病认知的提高，使得更多可治疗病例得以识别。医疗保健和政府机构正优先关注罕见疾病，致力于改善医疗服务可近性和报销机制。随着相关人员更加关注治疗效果、病患依从性和长期疗效，市场竞争格局也不断演变。技术进步，特别是新一代酵素替代疗法（如Glucosidaseα）和创新基因疗法，正在改善临床疗效。这个充满活力的市场由对公平医疗服务、以病人为中心的照护模式以及跨地域永续医疗保健政策的承诺所塑造。

全球庞贝氏症治疗市场驱动因素

全球庞贝氏症治疗市场的主要驱动因素是医疗专业人员和患者对庞贝氏症的认知度和盛行率不断提高。诊断技术的进步和基因检测使得庞贝氏症的早期发现成为可能，从而刺激了对有效治疗方案的需求。此外，酵素替代疗法和新型治疗方法的进展正在推动研发，製药公司正投入大量资金以满足尚未满足的医疗需求。患者支持组织和倡导活动的持续发展也在公众教育和治疗方案推广方面发挥关键作用，进一步推动了市场成长并促进了治疗方案的创新。

全球庞贝氏症治疗市场面临的限制因素

全球庞贝氏症治疗市场面临的主要限制因素之一是治疗方案的高成本，包括酵素替代疗法（ERT）和其他先进治疗方法。这些创新疗法往往伴随着沉重的经济负担，使得很大一部分患者和医疗系统难以负担，尤其是在中低收入国家。此外，核准治疗方法的数量有限，导致缺乏竞争，价格持续居高不下。这些经济障碍可能会限制患者获得所需治疗方法的机会，从而阻碍庞贝氏症治疗市场的整体成长和患者疗效。

全球庞贝氏症治疗市场趋势

塑造全球庞贝氏症治疗市场的关键趋势之一是对基因疗法日益增长的关注。基因疗法被视为一种突破性方法，能够提供长期且可能治癒的解决方案。与需要持续用药的传统酵素替代疗法不同，基因疗法透过矫正GAA酵素生成不足，针对庞贝氏症的根本遗传病因。这种模式转移反映了相关人员对基因疗法变革潜力的日益乐观，从而刺激了大量投资并加快了临床试验的步伐。随着医疗服务提供者和研究人员围绕着这项创新策略携手合作，市场有望在治疗方案和疗效方面迎来蓬勃发展。

目录

介绍

  • 调查目标
  • 调查范围
  • 定义

调查方法

  • 资讯收集
  • 二手资料和一手资料方法
  • 市场规模预测
  • 市场假设与限制

执行摘要

  • 全球市场展望
  • 供需趋势分析
  • 细分市场机会分析

市场动态与展望

  • 市场概览
  • 市场规模
  • 市场动态
    • 驱动因素和机会
    • 限制与挑战
  • 波特分析

关键市场考察

  • 关键成功因素
  • 竞争程度
  • 关键投资机会
  • 市场生态系统
  • 市场吸引力指数（2024）
  • PESTEL 分析
  • 总体经济指标
  • 价值链分析
  • 定价分析

庞贝氏症治疗市场规模（按类型和复合年增长率划分）（2025-2032 年）

  • 市场概览
  • 经典婴儿型
  • 非典型婴儿型
  • 晚髮型
  • 其他的

庞贝氏症治疗市场规模（按诊断和复合年增长率划分）（2025-2032 年）

  • 市场概览
  • 血液检查
  • 基因检测
  • 产前检查
  • 其他的

庞贝氏症治疗市场规模（依疾病类型划分）及复合年增长率（2025-2032 年）

  • 市场概览
  • 婴儿型庞贝氏症
  • 晚髮型庞贝氏症
  • 经典型庞贝氏症

庞贝氏症治疗市场规模：依治疗方法及复合年增长率划分（2025-2032 年）

  • 市场概览
  • 酵素替代疗法
  • 支持性护理
  • 其他的

庞贝氏症治疗市场规模（依给药途径及复合年增长率划分）（2025-2032 年）

  • 市场概览
  • 口服
  • 肠外
  • 其他的

庞贝氏症治疗市场规模（依通路划分）及复合年增长率（2025-2032 年）

  • 市场概览
  • 医院药房
  • 网路药房
  • 零售药局

庞贝氏症治疗市场规模（依最终用户划分）及复合年增长率（2025-2032 年）

  • 市场概览
  • 医院
  • 居家照护
  • 专业中心
  • 其他的

庞贝氏症治疗市场规模及复合年增长率（2025-2032）

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 义大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地区
  • 中东和非洲
    • 海湾合作委员会国家
    • 南非
    • 其他中东和非洲地区

竞争资讯

  • 前五大公司对比
  • 主要企业的市场定位（2024 年）
  • 主要市场参与者所采取的策略
  • 近期市场趋势
  • 公司市占率分析（2024 年）
  • 主要企业简介
    • 公司详情
    • 产品系列分析
    • 依业务板块进行公司股票分析
    • 2022-2024年收益年比比较

主要企业简介

  • Sanofi（France）
  • Amicus Therapeutics, Inc.（USA）
  • Astellas Pharma（Japan）
  • Roche（Switzerland）
  • Shionogi & Co., Ltd.（Japan）
  • Maze Therapeutics, Inc.（USA）
  • Spark Therapeutics（USA）
  • AVROBIO, Inc.（USA）
  • Asklepios Biopharmaceutical（USA）
  • Takeda Pharmaceutical Company Limited（Japan）
  • BioMarin Pharmaceutical Inc.（USA）
  • Genethon（France）
  • Entrada Therapeutics（USA）
  • Oxyrane（Belgium）
  • Aro Biotherapeutics（USA）
  • Valerion Therapeutics（USA）
  • Actus Therapeutics（USA）
  • M6P Therapeutics（USA）
  • GeneCradle Pharmaceutical（China）
  • Centogene AG（Germany）

结论与建议

简介目录
Product Code: SQMIG35D2353

Global Pompe Disease Treatment Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.24 billion in 2024 to USD 3.83 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

The global Pompe disease treatment market is witnessing robust growth, fueled by a rising incidence of the condition and an increased demand for effective therapies. Enhanced diagnostic capabilities and heightened awareness among healthcare professionals and patients have led to a broader identification of treatable cases. Initiatives from health organizations and governments are prioritizing rare diseases, facilitating better access and reimbursement structures. The competitive landscape is evolving as stakeholders focus on treatment efficacy, patient adherence, and long-term outcomes. Advancements in technology, particularly next-generation enzyme replacement therapies like avalglucosidase alfa and innovative gene therapy approaches, are providing improved clinical responses. This dynamic market is shaped by a commitment to equitable access, patient-centered care models, and sustainable healthcare policies across diverse regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pompe Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pompe Disease Treatment Market Segments Analysis

Global Pompe Disease Treatment Market is segmented by Type, Diagnosis, Disease Type, Treatment, Route of Administration, Distribution Channel, End User and region. Based on Type, the market is segmented into Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form and Others. Based on Diagnosis, the market is segmented into Blood Test, Genetic Test, Prenatal Test and Others. Based on Disease Type, the market is segmented into Infantile Pompe Disease, Late-Onset Pompe Disease and Classical Pompe Disease. Based on Treatment, the market is segmented into Enzyme Replacement Therapy, Supportive Therapies and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pompe Disease Treatment Market

A significant market driver for the Global Pompe Disease Treatment Market is the increasing prevalence and awareness of Pompe disease among healthcare professionals and patients. Enhanced diagnostic techniques and genetic testing have led to early identification of the condition, spurring demand for effective treatment options. Additionally, advancements in enzyme replacement therapy and novel therapeutic approaches are encouraging research and development, with pharmaceutical companies investing heavily to address unmet medical needs. Greater patient support organizations and advocacy initiatives also play a crucial role in educating the public and promoting treatment options, further propelling market growth and driving innovations in therapeutic solutions.

Restraints in the Global Pompe Disease Treatment Market

One significant market restraint for the Global Pompe Disease Treatment Market is the high cost associated with treatment options, including enzyme replacement therapies (ERTs) and other advanced therapeutic methods. These innovative treatments often come with substantial financial burdens, making them inaccessible for a large portion of patients and healthcare systems, particularly in low- and middle-income countries. Additionally, the limited number of approved therapies creates a lack of competition, leading to sustained high prices. This economic barrier can limit patient access to necessary treatments, thus hindering overall market growth and patient outcomes in managing Pompe disease.

Market Trends of the Global Pompe Disease Treatment Market

A significant trend shaping the Global Pompe Disease Treatment market is the increasing focus on gene therapy, viewed as a revolutionary approach for long-term, potentially curative solutions. Unlike traditional enzyme replacement therapies that require ongoing administration, gene therapy targets the underlying genetic cause of Pompe disease by correcting the deficiency in the GAA enzyme production. This paradigm shift has catalyzed substantial investments and accelerated the pace of clinical trials, reflecting heightened optimism among stakeholders about the transformative potential of gene therapy. As healthcare providers and researchers unite around this innovative strategy, the market is poised for dynamic evolution in treatment options and outcomes.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis

Global Pompe Disease Treatment Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Classic Infantile Form
  • Non-Classic Infantile Form
  • Late-Onset Form
  • Others

Global Pompe Disease Treatment Market Size by Diagnosis & CAGR (2025-2032)

  • Market Overview
  • Blood Test
  • Genetic Test
  • Prenatal Test
  • Others

Global Pompe Disease Treatment Market Size by Disease Type & CAGR (2025-2032)

  • Market Overview
  • Infantile Pompe Disease
  • Late-Onset Pompe Disease
  • Classical Pompe Disease

Global Pompe Disease Treatment Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Enzyme Replacement Therapy
  • Supportive Therapies
  • Others

Global Pompe Disease Treatment Market Size by Route of Administration & CAGR (2025-2032)

  • Market Overview
  • Oral
  • Parenteral
  • Others

Global Pompe Disease Treatment Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Global Pompe Disease Treatment Market Size by End User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Homecare
  • Specialty Centers
  • Others

Global Pompe Disease Treatment Market Size & CAGR (2025-2032)

  • North America (Type, Diagnosis, Disease Type, Treatment, Route of Administration, Distribution Channel, End User)
    • US
    • Canada
  • Europe (Type, Diagnosis, Disease Type, Treatment, Route of Administration, Distribution Channel, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Type, Diagnosis, Disease Type, Treatment, Route of Administration, Distribution Channel, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Type, Diagnosis, Disease Type, Treatment, Route of Administration, Distribution Channel, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Type, Diagnosis, Disease Type, Treatment, Route of Administration, Distribution Channel, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amicus Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Astellas Pharma (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shionogi & Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Maze Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Spark Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AVROBIO, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Asklepios Biopharmaceutical (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioMarin Pharmaceutical Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genethon (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Entrada Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Oxyrane (Belgium)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aro Biotherapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Valerion Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Actus Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • M6P Therapeutics (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GeneCradle Pharmaceutical (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Centogene AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations